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Drug Matrix cell C3: Management/supervision; Medical treatment
S  Seminal  studies  K  Key studies  R  Reviews  G  Guidance  MORE  Search for more studies
S  Leaders  affect performance of methadone maintenance cl inics  (1991). In s ix intens ively documented US cl inics , effective and experienced directors  were
associated with reduced drug use, injecting and crime among patients .
K  Training doctors  to del iver methadone maintenance treatment (1996). Based on experience in Austral ia , how to train out socia l ly derived atti tudes  to methadone
maintenance as  a  pol icy solution to a  socia l  problem and train in atti tudes  which place i t within mainstream medical  practice. Also incorporated in this  article
from the same author on qual i ty improvement in methadone services .
K  Receptive trainees  make training work (2004). US study at a  medical  centre’s  addictions  programme suggests  that recruiting the ‘right’ cl inicians  who have not
been trained in motivational  interviewing would be better than choosing the ‘wrong’ ones  who have been, and the former gain most from training.
K  Supervised consumption cuts  methadone deaths  (2010). From the mid 1990s  Bri tish addiction treatment cl inics  started to require patients  to take their
methadone under medical  supervis ion, preventing divers ion to the i l l i ci t market and thousands of overdose deaths.
K  Doing without supervised consumption (2012). What happens when after three months  opiate-addicted patients  are no longer required to take their methadone
under supervis ion? In Scotland this  was  tried in the fi rst UK randomised tria l ; patients  stayed longer in treatment and there was no escalation in heroin use, but
dai ly supervis ion was associated with less  extens ive heavy drinking.
K  Counsel l ing not needed in methadone maintenance (2012). In this  randomised tria l , cut-down US methadone programmes (cons isting of l i ttle more than
prescribing and enough overs ight to maintain safety) reduced substance use and crime as  effectively as  standard programmes with more counsel l ing. The same
was true regardless  of whether the patient was  under criminal  justice supervis ion (2013), and of reductions  in the risk of blood-borne disease (2013).
K  Counsel l ing does  not a id buprenorphine-based detoxi fication (2011). From the USA, the fi rst large-scale randomised tria l  involving patients  dependent on
prescription opioids  found that despite wanting to detoxi fy, a l l  but a  few relapsed after withdrawal  from substi tute medication; specia l is t drug counsel l ing did not
improve on medical  care a lone.
K  Methadone programme loosens  up, increases  capacity, patients  do just as  wel l  (2004). Canadian study documents  what happens when you ‘deregulate’
methadone prescribing and permit greater patient choice in treatment and treatment goals . Result: room for more patients , less  confl ict and no decrease in
effectiveness .
K  Bri tish GPs  as  effective as  specia l is t methadone cl inics  (2003). A two-year fol low-up of opiate dependent patients  sampled by the national  Engl ish NTORS study
showed that experienced or supported GPs can provide methadone maintenance treatment at least as  effectively as  specia l is t cl inics .
K  Why not let methadone patients  choose their dose? (2002). US study shows that methadone maintenance patients  a l lowed to set their own doses  do not escalate
excess ively. Benefi ts  may include improved patient-therapist relations  and reduced i l l i ci t drug use. Extended text reviews other relevant studies .
R  High-dose methadone most effective (Cochrane review, 2006). Higher dos ing is  the most sol idly establ ished success  factor in methadone maintenance. This
authori tative review finds  doses  averaging across  a  caseload 60 to 100 mg/day are more effective than lower dosages  in retaining patients  and in reducing use of
heroin and cocaine during treatment.
R  Strategies  for implementing the evidence ([Austral ian] National  Centre for Education and Training on Addiction, 2008). Lessons  from health promotion and
medical  care on how to improve addiction treatment practice by introducing research-based innovations, including common medical  education and training
strategies .
R  Prescribing therapy with the methadone does  not help (Cochrane review, 2011). Authori tative review of rigorous  studies  found that adding psychosocial  therapy
to opiate substi tute prescribing plus  routine counsel l ing has  overal l  made no s igni ficant di fference to retention or substance use.
G  Medication-based treatment as  a  route to recovery ([UK] National  Treatment Agency for Substance Misuse, 2012). UK cl inical  consensus  including how
methadone cl inics  and other medication-based treatment services  can be (re)oriented to long-term recovery.
G  Pharmacological  treatment of opioid dependence (World Health Organization, 2009). Chapter five offers  guidel ines  for programme managers  and cl inical
leaders .
G  Pharmaceutical  services  for drug users  ([UK] National  Treatment Agency for Substance Misuse, 2006). How pharmacies  can/should contribute to treating and
reducing harm from problem drug use.
G  What UK doctors  should do and be able to do ([UK] Royal  Col lege of Psychiatrists  and Royal  Col lege of General  Practi tioners , 2012). Guidance from UK
profess ional  associations  for GPs  and for psychiatrists  on the competencies , tra ining and qual i fications  expected of doctors  involved in caring for substance
users , from general is ts  such as  doctors  in emergency departments , to general  practi tioners  and addiction special is ts . See also this  guide ([UK] Publ ic Health
England, Royal  Col lege of Psychiatrists  and Royal  Col lege of General  Practi tioners , 2014) for more on the roles  and competencies  expected of doctors  specia l is ing
in addiction.
G  What US special is t addiction doctors  should do and be able to do ([US] American Society of Addiction Medicine, 2014). Consensus  guidel ines  from the US
profess ional  association for doctors  specia l is ing in addiction on what they are expected to do and the standards  they should meet. Intended to a id treatment
service managements  improve the qual i ty of their provis ion.
MORE  This  search retrieves  a l l  relevant analyses .
For subtopics  go to the subject search page.
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What is this cell about? About the treatment of drug dependence in a medical context and/or involving medical care. Medications are
the main distinguishing feature, but treatment also entails potentially therapeutic interactions with clinical and other staff. All these
processes are themselves affected by the management functions of selecting, training and managing staff, and managing the
intervention programme. In highly controlled studies, it may be possible to divorce the impact of interventions from the management of
the service delivering them, but in everyday practice, whether interventions get adopted and adequately implemented, and whether staff
(see cell B3) are able to develop and maintain appropriate attitudes and knowledge, depend on management and supervision. Within this
topic, the most researched has been the management of opiate substitute prescribing programmes.
Where should I start? We suggest this UK guidance on how methadone clinics and other medication-based treatment services can be
(re)oriented to long-term recovery. Turn to the Findings analysis and click the title to download the report. Then turn to pages 8 and 9, the
“For Services” section of a table on how to recognise whether your service is recovery-orientated. Note the advice to assess patients’
“recovery capital” – their social network/support, financial resources, education, mental health, and the (sub)cultural norms they have
assimilated. Together with the complexity of their problems, these, it is said, should help decide whether long-term treatment is likely to
be needed. Note too the insistence on mutual aid and/or peer support playing a role at various stages in treatment, helping to make
”pathways through and out of treatment ... visible.” That relates to the guidance’s vision of treatment as a dynamic, goal-orientated
movement. Ideally it leads to sustainably drug-free treatment exit, the opposite of ‘parking’, the accusation levelled at current services.
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Is a quietly parked life what some people want though, or can reasonably achieve, and is the preservation of gains that get no greater
sufficient justification for continued medication? The guidance also wants services to adhere to the evidence; that is strongly in favour of
indefinite, high-dose maintenance, practically silent on mutual aid in the context of methadone and allied programmes, does not suggest
counsellors in recovery are most effective in promoting recovery, is silent on whether recovery capital is indicative of required treatment
longevity, and at best equivocal (see Does counselling and therapy help? below) about the value of extra psychosocial support. You could
look at each of the recommendations in this section of the table, and ask yourself, is it reasonable, supported by evidence, and feasible,
and as a whole, would they transform a typical service in to a recovery-orientated service? If needed, check back on what ‘recovery’ is
generally taken to mean.
Highlighted study Dose is certainly not everything in methadone maintenance – relationships and good management count too – but this
review and meta-analysis for the Cochrane collaboration reveals just how important dose is. The main findings were apparent in the 11
trials which randomly allocated patients to different doses, the best way to eliminate other influences such as which types of patients or
services opt for higher doses. According to the authors, the results “support the conclusion that methadone dosages ranging from 60 to
100 mg/day are more effective than lower dosages in retaining patients and in reducing use of heroin and cocaine during treatment.”
They also warn of some resistance to acting on this finding, “to a certain extent driven by ideological assumptions about the nature of
opioid addiction.”
Partly they are referring to the divide between visions of heroin addiction as a long-term condition requiring long-term ameliorative
treatment (extended retention is good) versus something more like a bout of illness to first be stabilised by a short period of maintenance
(extended retention is bad) before complete recovery through detoxification. The flaw in the former is that few patients actually do
maintain unbroken, long-term retention, and in the latter, that sometimes virtually none complete the detoxification and stay abstinent.
Within these opposed “ideological” treatment philosophies, high doses are either a villain ensnaring patients in treatment due to the
difficulty of withdrawal, or a protective embrace which keeps them stable, safe from illicit opiate use, and in close contact with treatment
and associated medical and psychosocial services.
Issues to think about
 Can we let the patient choose their dose? The main studies analysed in the review highlighted above took no account of clinical
judgement or patient needs or wishes in allocating them to doses; it was all settled by a virtual roll of the dice. But in real life dosing is or
should be individualised. Who knows better than the individual themself whether their methadone is dousing their craving for illicit
heroin without undue sedation? A change of policy at a US clinic to allow patients to set doses offered the chance to evaluate this
proposition. You will see that average doses barely increased, and illicit opiate use became rarer than it had been before the change. The
background notes on the study reveal this is no isolated finding, and that “When doses are allowed to rise (or fall) to individually
appropriate levels, the absolute level of the dose has been found to no longer predict how long individuals stay in treatment or how well
they do.” It seems that the review highlighted above found higher doses more effective only because its main studies precluded
individualised dosing. The background notes also add an important rider: Yes, flexible dosing responsive to individual need can transform
‘failing’ patients in to successes, but “Whether the flexibility is nominally in the hands of staff or the patients is less important”.
This then is the context. We suggest you read the background notes on the study, which itemise what at the time were the other relevant
studies. You could ask yourself: Would patient self-regulation of dose work at my clinic or the ones I know? What sorts of patients might
be offered it; only those already stable and who have showed commitment to curbing heroin use, or (as in study 3 in the notes) all the
patients coming to a clinic? Perhaps it is more important to offer self-regulation to patients not doing well, to give them a chance to do
better. What effect would self-regulation have on relationships and the roles of the patients? It should reduce opportunities for friction
over dose levels and the time devoted to agreeing these, creating scope for more therapeutic discussions. It empowers the patient and
heightens their responsibility for their care, and generally it seems, they respond responsibly. But in the end, can a health professional
abrogate responsibility for controlling this core aspect of the patient’s care? Is the patient’s motivation the key factor? What of those who
want to minimise their methadone dose so they can continue to ‘enjoy’ heroin? Should this be allowed with a view to at least keeping
them in treatment? Must supervised consumption (discussed below) be strictly imposed to prevent patients bumping up their doses so
they have some spare to sell? The consequences of such a policy are potentially huge. All the more surprising then that in practice, it has
made so little difference.
 Do counselling and therapy help? In some quarters this is a virtually heretical question and the need for regular counselling is
enshrined in regulations governing medical programmes. Look for example at these World Health Organization guidelines which even in
their title (Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence) integrally partner the drug part of
the treatment of opioid dependence with “comprehensive psychosocial support to every patient”. The UK’s own guidelines also support
psychosocial adjuncts to methadone.
How then can it be that in well controlled studies, evidence of the effectiveness of extra psychosocial support is surprisingly thin? Take a
look at this US methadone maintenance study. In a seemingly unpromising caseload with on average over 20 years of heroin use and over
four years in jail behind them, patients who started their first four months of treatment (the ‘interim’ phase) virtually without counselling
did as well as those individually counselled about once a month, and even as well as those counselled once a fortnight by a counsellor
handpicked for excellence. However, this counsellor’s patients achieved these improvements in a different way – on lower doses and
with more leaving treatment. This review also found (non-significantly) that with therapy, more methadone patients managed to do at
least for a time without illicit opiate-type drugs and more left treatment.
In detoxification programmes too, adding specialist counselling to medical care does not necessarily protect the vast majority of patients
from relapsing after withdrawal from substitute medication – as in this US study of patients dependent on prescription opioids.
But even if when averaged across all patients, counselling and therapy seem to make little difference, inevitably there are exceptions,
among whom may be the psychologically unstable patients often excluded from trials and multiply problematic clients who without
support suffer repeated crises.
Look at our analysis of an important methadone study, these notes which reviewed other similar studies, and this Findings hot topic on
counselling in methadone programmes. Consider the implications of taking the big step (for all or selected patients) of doing without
anything other than the minimum keyworking required for safety and monitoring. Is this effectively to abandon recovery objectives and
accept ’parking’ on methadone (see discussion under Where should I start?)? Perhaps expert and intensive counselling does not make
much difference while patients are in treatment, but enables more to do without illicit drugs and leave safely? Should counselling be
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mandatory, or can patients take it or leave it? There are caveats and confounds and limitations in the few directly relevant studies. Is the
evidence sufficient to affect practice?
 Have we got the balance right on supervised consumption? Mandatory in US methadone programmes, UK clinics have only relatively
recently required patients to consume their medication under the eyes of staff at the clinic or (more usually) at the pharmacy. The aim
was primarily to prevent patients diverting their supplies to the illicit market, risking the lives of non-patients, but also to protect patients
themselves by ensuring they took their medication, could not ‘hoard’ supplies, and by monitoring the risky initial weeks of prescribing. UK
guidance recommends supervised consumption for “around three months” and “longer in patients who fail to respond to conventional
treatment.”
What are the pros and cons? First, in Britain each dose of methadone taken under the eyes of staff seems considerably less likely to be
involved in an overdose death (not just of methadone patients, but anyone) than when the drug is taken unsupervised. But that is not the
whole picture. What if patients who would have entered or stayed in treatment do not because of this unpopular requirement, which
many find difficult to stick to due to the need for near-daily attendance and the impact his has on getting on with their lives. As a result,
some may drop out and return fully to the illicit market. Then there is the ‘opportunity cost’ of supervision – money and time that could
have been spent extending the benefits of treatment to more patients. Relaxing this requirement was part of the package which meant a
Canadian clinic could treat more patients without any detriment to outcomes.
These kinds of influences could mean that imposing supervision results in fewer deaths from diverted methadone, but more from heroin
and other illegally-sourced opiate-type drugs among untreated addicts, or those who leave or are discharged prematurely. Relaxing
supervision might lead to the reverse pattern.
What we know for sure is very little, especially for the UK. A very rare randomised trial from Scotland suggested that for stabilised
patients, extending supervision beyond the currently recommended three months means more will leave treatment early, but while they
are there, fewer may drink heavily. The bigger picture was how little difference it made. In England the NTORS study which recruited its
patients in 1995 compared GP-led methadone services with hospital clinics. Three-quarters of the clinics required patients to take their
methadone under supervision, but just one of the GP programmes. Two years after entering treatment, GP and clinic patients had
improved substantially and to roughly the same degree, but what differences there were in drug use, psychological health and retention,
favoured the GPs.
To further explore this complex issue read these Findings notes. Other analyses related to supervised consumption can be found by
running this search. On the basis of what you have read, if you managed a methadone programme, would you opt to have relaxed
supervision requirements for most patients, or would you feel the evidence warranted more extended and universal supervision? Is the
key thing clinical judgment of when it is right for that individual to change their supervision regimen (a proposition which has never been
tested)? On such decisions could rest thousands of lives just within Britain.
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